A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Clinical trial NCT06764875 · RECRUITING
Trial details
- NCT number
- NCT06764875
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-01
- Primary completion
- 2029-04-27
- Enrollment
- 840
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.